Pfizer Inc. (NYSE: PFE) today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months. For a third primary endpoint, the rate of DAS28-4(ESR) <2.6, a measure of disease remission, treatment with tasocitinib resulted in a numerically greater, but not statistically significant difference from placebo at three months.
In ORAL Solo, a similar frequency of adverse events was seen across all treatment groups. Serious adverse events were reported in 4.1 percent of patients. Additionally, decreases in neutrophil count and hemoglobin and an increase in cholesterol occurred by month three. These changes tended to stabilize thereafter. No new safety signals were detected.
"We are encouraged by the statistically significant and clinically meaningful improvements we observed in a proportion of patients treated with tasocitinib monotherapy in ORAL Solo," said Roy Fleischmann, MD, Clinical Professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center in Dallas. "Further research into additional treatment options for patients with moderately to severely active RA is important, and we look forward to seeing the results of the additional Phase 3 ORAL trials of tasocitinib."
ORAL Sequel (1024), an open label, follow-up Phase 2/3 study, had safety findings consistent with the global Phase 2 RA clinical program and showed sustained efficacy over 24 months when tasocitinib was administered as monotherapy or in combination with methotrexate.
Results of both studies will be presented at the American College of Rheumatology (ACR) Annual Meeting in Atlanta this week.
ORAL Solo (1045): Trial Design and Results
ORAL Solo was a six-month, double-blind, placebo-controlled study of 611 randomized patients. Patients with moderately to severely active RA who had an inadequate response to at least one disease- modifying antirheumatic drug (DMARD) received tasocitinib 5 mg or 10 mg monotherapy or placebo twice a day. After three months of treatment, patients randomized to the placebo group began receiving tasocitinib 5 mg or 10 mg in a blinded manner. Primary efficacy endpoints were ACR20 response rates (20 percent improvement from baseline in the American College of Rheumatology scale), mean change in HAQ-DI (Health Assessment Questionnaire Disability Index) and DAS (Disease Activity Score) 28-4(ESR) (DAS28) <2.6, all at month three. Secondary endpoints included ACR50/70 response rates and mean change in DAS28.
Efficacy Overview (all results were measured at three months):
+/- Primary efficacy endpoint; *p<0.0001; **p<0.05
ACR20/50/70, HAQ-DI and DAS28 measurements showed both a dose effect and improvement over time. ACR20 showed separation from placebo by week two, the first time point measured after baseline.
The safety findings in ORAL Solo were consistent with those observed in the global Phase 2 RA clinical program. In months 0-3 and months 3-6 of the study, respectively, 54.1 percent and 40.0 percent of patients had adverse events (AEs) and 2.1 percent and 1.0 percent discontinued due to these AEs, with similar frequency across groups. Twenty five patients (4.1 percent) had serious AEs and serious infections were reported in six patients during the total six months of the study. Among patients treated with tasocitinib, there were statistically significant decreases in neutrophil count, statistically significant increases in LDL and HDL cholesterol and not statistically significant changes in hemoglobin levels. These changes were seen at month three and were stable thereafter. During the course of the study, few patients had transaminase elevations distributed across all groups.
ORAL Sequel (1024): Trial Design and Results
ORAL Sequel is an ongoing Phase 2/3 study designed to evaluate the long-term safety and efficacy of tasocitinib 5 mg or 10 mg twice daily in the treatment of moderately to severely active RA in patients who have participated in a prior randomized study of tasocitinib and then rolled over to this open label extension study. The primary endpoints are laboratory safety data and AE reports. Secondary endpoints include ACR20/50/70 response rates and mean change in DAS28 and HAQ-DI.
Safety and efficacy were evaluated over 24 months in 1,070 patients, and compared between patients who received tasocitinib monotherapy and tasocitinib in combination with methotrexate.
ACR response rates showed a trend for improvement over time (month 1-24) with similar ACR20 response rates in tasocitinib monotherapy and tasocitinib on background methotrexate groups at month 24. The mean DAS28 and HAQ-DI scores also improved compared to baseline and remained consistent over time.
No new safety signals emerged in ORAL Sequel. For all patients, the most frequent AEs were bronchitis, upper respiratory infection and urinary tract infection. 6.3 percent of patients discontinued from the study due to AEs. The most frequently reported class of serious AEs was infections>